BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 9417515)

  • 1. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
    Metzger S; Hofmann H
    Mycoses; 1997; 40 Suppl 1():56-63. PubMed ID: 9417515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.
    Cartledge JD; Midgley J; Gazzard BG
    AIDS; 1997 Dec; 11(15):1839-44. PubMed ID: 9412702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
    Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
    AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.
    Hundt W; Hofmann H
    Infection; 1994; 22(2):124-31. PubMed ID: 8070926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents.
    Arias A; Arévalo MP; Andreu A; Rodríguez C; Sierra A
    Mycoses; 1994; 37(7-8):285-9. PubMed ID: 7739661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.
    Menon T; Umamaheswari K; Kumarasamy N; Solomon S; Thyagarajan SP
    Acta Trop; 2001 Oct; 80(2):151-4. PubMed ID: 11600094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
    Chryssanthou E; Torssander J; Petrini B
    Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
    Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
    J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
    Johnson EM; Warnock DW; Luker J; Porter SR; Scully C
    J Antimicrob Chemother; 1995 Jan; 35(1):103-14. PubMed ID: 7768758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.
    Sojakova M; Liptajova D; Borovsky M; Subik J
    Mycopathologia; 2004 Feb; 157(2):163-9. PubMed ID: 15119851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp.
    Wardle HM; Law D; Moore CB; Mason C; Denning DW
    Antimicrob Agents Chemother; 1995 Apr; 39(4):868-71. PubMed ID: 7785986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.
    Laguna F; Rodríguez-Tudela JL; Martínez-Súarez JV; Polo R; Valencia E; Díaz-Guerra TM; Dronda F; Pulido F
    Clin Infect Dis; 1997 Feb; 24(2):124-30. PubMed ID: 9114134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species.
    Johnson EM; Davey KG; Szekely A; Warnock DW
    J Antimicrob Chemother; 1995 Nov; 36(5):787-93. PubMed ID: 8626259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
    Martín E; Parras P; Lozano MC
    Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.
    Ruhnke M; Eigler A; Tennagen I; Geiseler B; Engelmann E; Trautmann M
    J Clin Microbiol; 1994 Sep; 32(9):2092-8. PubMed ID: 7814530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.